Molecular Neurodegeneration (Nov 2010)

Parkinson-related parkin reduces α-Synuclein phosphorylation in a gene transfer model

  • Rebeck GW,
  • Lashuel Hilal A,
  • Maguire-Zeiss Kathleen,
  • Feng Li,
  • Dumanis Sonya B,
  • Khandelwal Preeti J,
  • Moussa Charbel EH

DOI
https://doi.org/10.1186/1750-1326-5-47
Journal volume & issue
Vol. 5, no. 1
p. 47

Abstract

Read online

Abstract Background α-Synuclein aggregates in Lewy bodies and plays a central role in the pathogenesis of a group of neurodegenerative disorders, known as "Synucleinopathies", including Parkinson's disease. Parkin mutations result in loss of parkin E3-ubiquitin ligase activity and cause autosomal recessive early onset parkinsonism. Results We tested how these two genes interact by examining the effects of parkin on post-translational modification of α-Synuclein in gene transfer animal models, using a lentiviral gene delivery system into the striatum of 2-month old male Sprague Dawley rats. Viral expression of wild type α-Synuclein caused accumulation of α-Synuclein and was associated with increased cell death and inflammation. α-Synuclein increased PLK2 levels and GSK-3β activity and increased the levels of phosphorylated α-Synuclein and Tau. Parkin co-expression reduced the levels of phosphorylated α-Synuclein and attenuated cell death and inflammation. Parkin reduced PLK2 levels and increased PP2A activation. Conclusions These data suggest that parkin reduces α-Synuclein levels and alters the balance between phosphatase and kinase activities that affect the levels of phosphorylated α-Synuclein. These results indicate novel mechanisms for parkin protection against α-Synuclein-induced toxicity in PD.